More on TRDA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+4.7% Growth)
- Ratings (7.5 Score)

Upcoming Events

- Earnings (11/10/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Entrada Therapeutics (NQ:TRDA)
Delayed: 4.75 +0.34 (7.71%)
Prev. Close $4.41  
Open$4.52 
52 Wk High$ 
52 Wk Low$ 
Day High$4.95 
Day Low$4.46 
P/E N/A  
EPS$ 
Volume617,086 

Friends, Peers and Foes (?): AMLX, ANAB, ARWR, DRUG, MIRM (more...)

Oct 21, 2026 07:02 AM Entrada Therapeutics names Linea Aspesi as Chief People Officer
Oct 21, 2026 07:00 AM Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Oct 19, 2026 07:59 AM H.C. Wainwright Reiterates Neutral Rating on Entrada Therapeutics (TRDA)
Oct 14, 2026 07:52 AM Form 8-K Entrada Therapeutics, For: Oct 14
Oct 14, 2026 07:02 AM Entrada Therapeutics clears DMC review, advances DMD study to top dose
Oct 14, 2026 07:00 AM Entrada Therapeutics reports early DMD drug trial safety data
Oct 14, 2026 07:00 AM Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Oct 14, 2026 07:00 AM Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Sep 10, 2026 04:27 PM Form SCHEDULE 13D/A Entrada Therapeutics, Filed by: MPM BioVentures 2014, L.P.
Sep 10, 2026 07:00 AM Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
View All Articles

Entities mentioned with TRDA

View All Entities